about
When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transitionPharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancerImportance of relating efficacy measures to unbound drug concentrations for anti-infective agentsImplementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical ResearchComparison of Active Drug Concentrations in the Pulmonary Epithelial Lining Fluid and Interstitial Fluid of Calves Injected with Enrofloxacin, Florfenicol, Ceftiofur, or TulathromycinFuture technology insight: mass spectrometry imaging as a tool in drug research and development.Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosisInsights into the pharmacokinetic properties of antitubercular drugs.Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration.Measurement of tissue azithromycin levels in self-collected vaginal swabs post treatment using liquid chromatography and tandem mass spectrometry (LC-MS/MS).Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome.Antibiotic stability over six weeks in aqueous solution at body temperature with and without heat treatment that mimics the curing of bone cementBiopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin.Pharmacokinetic and pharmacodynamic modeling of cyadox against Clostridium perfringens in swine.In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TBMaternal intravenous administration of azithromycin results in significant fetal uptake in a sheep model of second trimester pregnancy.Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazoleExposure to phages has little impact on the evolution of bacterial antibiotic resistance on drug concentration gradients.Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery.Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.A physiologically based pharmacokinetic model for capreomycin.Drug compound characterization by mass spectrometry imaging in cancer tissue.Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal mouse tissues using high mass resolution MALDI-FTICR-mass spectrometry imaging.Novel insights in drug metabolism by MS imaging.Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin.Factors impacting unbound vancomycin concentrations in different patient populations.Pharmacokinetics of a single 1g dose of azithromycin in rectal tissue in men.Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration.Tissue distribution of enrofloxacin in African clawed frogs (Xenopus laevis) after intramuscular and subcutaneous administration.Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluidAtomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations.Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.Bone penetration of amoxicillin and clavulanic acid evaluated by population pharmacokinetics and Monte Carlo simulationSoft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysisPharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem celIntracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.
P2860
Q21145725-EB1F1608-A9EA-4DFA-B5A4-748154F8A9F8Q26825326-8C17AEAE-42AD-47F0-8D37-A80C937AD0ADQ26827380-62AC927B-9E42-4964-BE1B-AA29DF067211Q27024682-003BDCE1-72AC-434B-AD48-2211A3C802A0Q27322047-281894AA-54C5-4128-A890-49ED2E20263BQ28087460-CA361E72-BF41-4C0A-AD19-32A5A719D63BQ28542435-F6B5105E-9441-42C4-A1FC-B7F93E5C67FFQ30251497-1E0381E0-CE02-4551-964B-C06BD7185C22Q30685690-504F054A-53B5-44B1-8E5A-C77FC1BFDD10Q33675064-C40D03C3-5C97-4538-B6DA-4C3BCC784B54Q33749881-0A92BD74-D656-46BF-864A-9BAAF08D5852Q33759744-3D32C7D4-38B9-4580-A813-BE3A6DC7AD23Q33798218-9530889C-9AF6-4A88-B62E-FF6B6C20A67FQ33826396-8446E18F-62A2-4AC5-9B79-38CFFCBB0F11Q34591451-FF6FD7DF-C8C7-4AB7-9703-6087AE38BED7Q34596388-7A6135AC-D206-4D40-865B-EC3EC5CE4E0EQ35065903-FE2C0B0E-AA58-4D69-9535-CA86306A4269Q35130454-81C900F7-DD9C-4068-A6FC-BB266306DF60Q35364423-9826499B-E8C8-45A8-982E-3463C8468E08Q35607735-43D1CA84-0D58-4D6A-A7B8-01F0B570670AQ35666457-4937A431-66F3-4760-932F-E061CCBA678BQ35689199-1FC987CE-D8FA-4541-A54C-02443E840931Q35704471-4E10C182-1343-4E8B-9DEC-144D72F14BCCQ35806445-E2BB67A4-A46F-425E-B317-DA2C1B72917EQ35863164-2586C226-C5DE-4346-BA46-2A0F243851FAQ35936145-A1EEA85C-4FA0-403E-81B8-C85161F0ACB5Q35959546-D5B36A86-A87F-4E50-9DBE-FABCFD4E8EC7Q36158421-C0548166-6307-455A-A880-F971BAAA677BQ36325324-099ECD75-0618-4E77-8863-5500BC39C450Q36571957-5FF34331-5DDA-49CE-B4D0-8C2B3D33B418Q36761200-9400B389-3AA3-40E1-AD1B-C2F87F48692CQ36868273-4E863816-9910-4DB3-BC0D-8A8D9FF3B5D6Q36924714-07886BE3-BCC4-459A-8453-0F348E664A03Q36925745-181AD289-2D27-4EDA-B82B-381F106DD27BQ37115670-7F4E7BE5-BB3E-45C5-A67C-75A1FD982BE7Q37190660-BE442A8E-9337-4E85-A824-630D895D0E7BQ37204197-3DD14315-5285-4D43-9834-3F94703A287FQ37247602-B5B965D4-F3C2-4AD5-B2F8-3E0EB4C09829Q37333175-DD8A0FB0-455A-4F55-BE4B-136A8FD2A3B2Q37504548-EB26CA88-039D-4D2A-B8D2-B6AB28EB2C19
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tissue concentrations: do we ever learn?
@en
Tissue concentrations: do we ever learn?
@nl
type
label
Tissue concentrations: do we ever learn?
@en
Tissue concentrations: do we ever learn?
@nl
prefLabel
Tissue concentrations: do we ever learn?
@en
Tissue concentrations: do we ever learn?
@nl
P2093
P356
P1476
Tissue concentrations: do we ever learn?
@en
P2093
Hartmut Derendorf
Johan W Mouton
Ursula Theuretzbacher
William A Craig
P304
P356
10.1093/JAC/DKM476
P407
P577
2007-12-06T00:00:00Z